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CONCLUSIONS Increasing operator experience improves TR cannula-
tion failure and TF cross-over rates, reduces contrast dye dosing, and
shortens ﬂuoroscopy time. These data support an operator learning
curve of at least 200 cases to achieve optimal TR performance.
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BACKGROUND Vascular complications are frequent following trans-
catheter aortic valve replacement (TAVR) and are associated with
increased mortality and prolonged hospital stay. This study investi-
gated the vascular complications and clinical outcomes associated
with the use of the Prostar XL vascular closure system.
METHODS Between October 2008 and February 2015, 481 consecutive
patients underwent TAVR. A true percutaneous femoral approach was
performed in 323 patients (67.2%). The femoral artery diameter, tor-
tuosity and calciﬁcation were evaluated using CT. All complications
were deﬁned according to VARC-2 standardized endpoints. Successful
closure with ProStar XL was deﬁned as adequate hemostasis without
Prostar-related vascular complications. The incidence of vascular
complications in the early (2008-2011) and late (2012-2015) experience
of the TAVR program were compared.
RESULTS The mean age of the cohort was 79.148.77 years, 51.1% were
female, and mean logistic EuroScore was 21.212.7%. The vast majority of
cases used an 18F sheath (91.9%) and Medtronic CoreValve device (92.9%).
The mean minimal luminal diameter of the femoral artery was
8.111.20mm, themean sheath diameterwas 7.200.17mm, and themean
SFARwas0.900.12. Vascular complications occurred in 13.3%of the cohort
overall (15.2% vs. 12.0%, p¼0.467). Major vascular complications were
decreased in the late experience (7.9%vs. 3.3%, p¼0.079). ProStarXL failure
was more common in the early experience (10.8% vs. 4.9%, p¼0.09). There
wasnosigniﬁcantdifference in life-threatening/disablingbleeding (0.6%vs.
1.1%, p¼0.779), BARC major bleeding (4.3% vs. 2.2%, p¼0.286), or BARC
minor bleeding (8.6% vs. 2.8%; p¼0.206) in the latter group, despite higher
rates of moderate and severe tortuosity (p¼0.001), more cases with
SFAR1.05 (p¼0.04), and a trend towards more calciﬁed vessels (p¼0.09).
Overall ProStarXL failurewas 7.1%andwasmore frequently seen inpatients
with SFAR1.05 (p<0.001). On multivariate analysis, calcium score 2 or 3
(OR: 4.62, 95% CI: 2.01 to 10.63, p<0.001), minimal CT lumen diameter (OR
0.60: 95%CI: 0.40 to0.87,p¼0.009), andNYHAclass III/IV (OR0.20,95%CI:
0.06 to 0.62, p¼0.006) were independent predictors of vascular complica-
tions. Cardiovascular 30 day-mortality was similar in both early and late
groups (1.4% vs. 0.5%, p¼0.585).
CONCLUSIONS The experience of the ProStar XL device for femoral
artery closure reduced major vascular complications despite patients
referred for TAVI since 2012 have tended to have anatomically more
challenging femoral access when compared to cases referred previ-
ously. The ProStar XL device provides consistent, safe vascular
closure following TAVI.
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BACKGROUND Anatomic and physiologic changes that are induced
by radial access may lead to a decrease of upper limb function. This is
the ﬁrst study that investigated the effect of transradial (TR) access on
upper extremity function at long-term follow-up.
METHODS Between January 2013 and April 2014, upper limb function
was assessed in a total of 348 patients with complete 1-year follow-up
after coronary catheterization. Upper limb function was assessed with
the self-reported shortened version of the Disabilities of Arm, Shoul-
der, and Hand questionnaire. The presence and severity of upper
extremity cold intolerance was assessed with the self-reported Cold
Intolerance Symptom Severity questionnaire. Both questionnaires
were completed before the catheterization and at 1 year follow-up.
Higher scores represent worse upper limb functionality or symptoms.
The nonparametric Wilcoxon signed-rank test was used to assess the
change of upper limb function and symptoms over time.
RESULTS The mean age of the study population was 64 years, and 72%
of the population was male. Radial approach was performed in 300
patients. Box plots of QuickDASH scores at baseline and 1-year follow-
up for TR- and TF-treated patients can be appreciated in Figure 1.
Whiskers represent 5th to 95th percentiles. Upper limb function did
not change signiﬁcantly over time when catheterization was
performed through the radial artery (baseline 2.39 {IQR 0.00-13.64};
f-up 0.00 {IQR 0.00-11.02}) or femoral artery (5.68 {IQR 0.00-15.91}; f-
up 4.55 {IQR 0.00-17.05}). If we applied a Minimal Clinically
Important Difference of 14, 11% of the TR patients would have a
clinically-relevant increase of the QuickDASH, which was similar to
the TF treated patients (12.5 %, p¼0.76). Similarly, upper extremity
was not affected by cold intolerance after TR access (baseline 0.00
{IQR 0.00-13.75}; f-up 0.00 {IQR 0.00-0.00}, p¼0.09) or TF access
(baseline 0.00 {IQR 0.00-31.25]; f-up 0.00 {IQR 0.00-33.00}, p¼ 0.29).
The development of pathological cold intolerance (deﬁned as CISS 
30) was not associated with the applied access route (p ¼ 0.22).CONCLUSIONS At long-term follow-up upper limb function was not
affected when coronary catheterizations and interventions were per-
formed through the radial artery. The results of our study are of
importance to all patients undergoing TR access, especially when
optimal upper extremity function is essential.
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